(Q51149995)

31 March 2018

title

Risk prediction with proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with stable coronary disease on statin treatment. (English)

1 reference

31 March 2018

author name string

Christian Werner

1

1 reference

31 March 2018

Michael M Hoffmann

2

1 reference

31 March 2018

Karl Winkler

3

1 reference

31 March 2018

Michael Böhm

4

1 reference

31 March 2018

Ulrich Laufs

5

1 reference

31 March 2018

publication date

29 March 2014

1 reference

31 March 2018

published in

Vascular Pharmacology

1 reference

31 March 2018

volume

62

1 reference

31 March 2018

issue

2

1 reference

31 March 2018

page(s)

94-102

1 reference

31 March 2018

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.004

Proprotein convertases in health and disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.004

Cardiovascular endocrinology in 2012: PCSK9-an exciting target for reducing LDL-cholesterol levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.004

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.004

Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.004

AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.004

AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Sub

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.004

Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.004

Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.004

Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised con

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.004

Effect of a monoclonal antibody to PCSK9 on LDL cholesterol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.004

Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.004

Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.004

Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.004

Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.004

High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.004

Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.004

On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: a

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.004

Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.004

Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; Internat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.004

Universal definition of myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.004

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.004

Circulating endothelial progenitor cells and cardiovascular outcomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.004

Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.004

Improved efficacy for ezetimibe and rosuvastatin by attenuating the induction of PCSK9

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.004

Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.004

Proprotein convertase subtilisin/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.004

Plasma PCSK9 levels and clinical outcomes in the TNT (Treating to New Targets) trial: a nested case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.004

Beyond LDL cholesterol, a new role for PCSK9.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.004

Unexpected roles for PCSK9 in lipid metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.004

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.004

Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.004

Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.004

Genetic and metabolic determinants of plasma PCSK9 levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.004

Fenofibrate concomitantly decreases serum proprotein convertase subtilisin/kexin type 9 and very-low-density lipoprotein particle concentrations in statin-treated type 2 diabetic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.004

PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.03.004

10.1016/J.VPH.2014.03.004

7 January 2021

Identifiers

DOI

1 reference

31 March 2018

1 reference

31 March 2018